BioWorld International Correspondent

LONDON Cyclacel Ltd. announced a three-year collaboration with the University of Edinburgh under which two of the university’s professors will work exclusively for Cyclacel, applying rational drug design to more than 100 Cyclacel cell cycle targets.

Howard Marriage, executive director, business development, said the deal “is the logical next step in building a diversified drug pipeline from the large number of targets emerging out of our Polgen division.”

Financial details were not disclosed, but Cyclacel said that in addition to its own financial commitment, the collaboration received public money from the development agency Scottish Enterprise.

Cyclacel, based in Dundee, specializes in the discovery and development of small-molecule inhibitors of cell cycle targets for the treatment of cancer. The company has worked with researchers at Edinburgh University for several years, helping to validate the university’s Lidaeus docking-simulation engine, to which Cyclacel has an exclusive license. Cyclacel will develop versions of the software that incorporate its expertise in cell cycle target classes such as kinases and protein-protein interactions.

“Securing access to the university team, Lidaeus and the associated intellectual property will allow us to advance an increasing number of earlymstage programs from targets to development molecules,” Marriage said.